Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Treasury Shares (2021 - 2025)

Bioventus' Treasury Shares history spans 5 years, with the latest figure at $2.8 million for Q4 2025.

  • For Q4 2025, Treasury Shares changed N/A year-over-year to $2.8 million; the TTM value through Dec 2025 reached $2.8 million, changed N/A, while the annual FY2025 figure was $2.8 million, N/A changed from the prior year.
  • Treasury Shares reached $2.8 million in Q4 2025 per BVS's latest filing, up from $159000.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $3.9 million in Q1 2024 to a low of $159000.0 in Q3 2025.
  • Average Treasury Shares over 5 years is $1.7 million, with a median of $1.3 million recorded in 2022.
  • Peak YoY movement for Treasury Shares: skyrocketed 593.69% in 2022, then plummeted 94.32% in 2025.
  • A 5-year view of Treasury Shares shows it stood at $1.0 million in 2021, then grew by 16.11% to $1.2 million in 2022, then surged by 73.76% to $2.1 million in 2023, then surged by 35.53% to $2.8 million in 2024, then decreased by 0.82% to $2.8 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Treasury Shares are $2.8 million (Q4 2025), $159000.0 (Q3 2025), and $2.9 million (Q2 2025).